Aptevo Therapeutics Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aptevo Therapeutics Inc. on March 7, 2023, reporting events that occurred on March 3, 2023. The filing details significant changes to the Company's executive leadership structure.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive appointments and compensation arrangements.
Material Changes
On March 3, 2023, the Company announced the following executive appointments and compensation packages:
- Jeffrey G. Lamothe: Appointed as Executive Vice President and Chief Operating Officer (previously Executive Vice President and Chief Financial Officer).
- Annual Base Salary: $470,000.
- Annual Bonus Target: 45% of base salary.
- Equity Grant: 16,500 options and 16,500 restricted stock units (vesting in three equal annual installments).
- Daphne Taylor: Appointed as Senior Vice President and Chief Financial Officer (previously Senior Vice President, Finance).
- Annual Base Salary: $403,745.
- Annual Bonus Target: 40% of base salary.
- Equity Grant: 11,000 options and 11,000 restricted stock units (vesting in three equal annual installments).
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard disclosure that there are no family relationships or reportable transactions under Item 404(a) of Regulation S-K involving the new appointees.
Key Facts for Investor Verification
- Verify the vesting schedules and performance conditions for the equity grants issued to Mr. Lamothe and Ms. Taylor under the 2018 Stock Incentive Plan.
- Confirm the impact of these leadership changes on the Company's strategic direction and financial reporting processes.
- Review the Company's most recent 10-K or 10-Q for current cash position and burn rate, as this 8-K does not disclose financial status.